{
    "id": 481,
    "fullName": "ALK L1196M",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ALK L1196M lies within the protein kinase domain of the Alk protein (UniProt.org). L1196M is predicted to confer a gain of function to the Alk protein as demonstrated by transformation activity and modest autophosphorylation of Alk in culture (PMID: 25517749), and confers resistance to Alk inhibitors in the context of ALK rearrangements in culture and in vivo (PMID: 21613408, PMID: 25421750, PMID: 31452835).",
            "references": [
                {
                    "id": 4535,
                    "pubMedId": 25517749,
                    "title": "ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25517749"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2442,
                    "pubMedId": 21613408,
                    "title": "Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613408"
                },
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                },
                {
                    "id": 17665,
                    "pubMedId": 31452835,
                    "title": "ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31452835"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "L1196M",
    "createDate": "05/02/2014",
    "updateDate": "01/27/2020",
    "referenceTranscriptCoordinates": {
        "id": 102059,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29220765G>T",
        "cDna": "c.3586C>A",
        "protein": "p.L1196M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5834,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited cell proliferation in transformed cell lines over expressing ALK L1196M in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",
            "molecularProfile": {
                "id": 537,
                "profileName": "ALK L1196M"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5176,
                    "pubMedId": null,
                    "title": "The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors",
                    "url": "http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=055d4461-9793-4f83-b663-f356d9ae0fdb&cKey=ff6f8d25-f06a-4ae4-9dbf-7e390ef45123&mKey={1D10D749-4B6A-4AB3-BCD4-F80FB1922267}"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16906,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WX-0593 inhibited growth of transformed cells expressing ALK L1196M in the context of EML4-ALK in culture (Cancer Res 2018;78(13 Suppl):Abstract nr 4794).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 8236,
                "therapyName": "WX-0593",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15046,
                    "pubMedId": null,
                    "title": "Preclinical evaluation of WX-0593, a potent orally active ALK inhibitor",
                    "url": "http://cancerres.aacrjournals.org/content/78/13_Supplement/4794.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10341,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in cell line xenograft models (PMID: 21575866).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 1817,
                    "pubMedId": 21575866,
                    "title": "CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21575866"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5701,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17759,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 24887559).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 15763,
                    "pubMedId": 24887559,
                    "title": "Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24887559"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17801,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2095,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2442,
                    "pubMedId": 21613408,
                    "title": "Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21613408"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12859,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 683,
                    "pubMedId": 22277784,
                    "title": "Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22277784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17805,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2094,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK L1196M in the context of EML4-ALK were insensitive to Xalkori (crizotinib) as demonstrated by a lack of growth inhibition and Alk phosphorylation in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17802,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2965,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of non-small cell lung cancer cells expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3553,
                    "pubMedId": 21502504,
                    "title": "Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21502504"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18599,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, EML4-ALK and ALK L1196M were identified as acquired mutations in the pleural effusion from a patient with lung adenocarcinoma after his disease progressed on Xalkori (crizotinib) treatment (PMID: 28434515).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14590,
                    "pubMedId": 28434515,
                    "title": "Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain\u00a0after Sequential Use of ALK Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28434515"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8338,
                    "pubMedId": null,
                    "title": "TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants",
                    "url": "http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5702,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17804,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited proliferation of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5708,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                },
                {
                    "id": 6706,
                    "pubMedId": 27432227,
                    "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27432227"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2650,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3367,
                    "pubMedId": 26144315,
                    "title": "PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26144315"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5638,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Rozlytrek (entrectinib), resulting in anti-proliferative activity in culture (PMID: 26939704).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5130,
                    "pubMedId": 26939704,
                    "title": "Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26939704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17803,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated moderate resistance to ASP3026 in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2056,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).",
            "molecularProfile": {
                "id": 5335,
                "profileName": "EML4 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2525,
                    "pubMedId": 24675041,
                    "title": "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24675041"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17822,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3454,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3466,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17764,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited ALK phosphorylation and proliferation of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17767,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated moderate resistance to Zykadia (ceritinib) in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3485,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3554,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17766,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated resistance to ASP3026 in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17765,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M demonstrated moderate resistance to Alunbrig (brigatinib) in culture (PMID: 25727400).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 2573,
                    "pubMedId": 25727400,
                    "title": "Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25727400"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3437,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13320,
                "profileName": "NPM1 - ALK ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3460,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13328,
                "profileName": "NPM1 - ALK ALK L1122V ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13328,
                "profileName": "NPM1 - ALK ALK L1122V ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 50744,
                "name": "anaplastic large cell lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13328,
                "profileName": "NPM1 - ALK ALK L1122V ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3552,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13328,
                "profileName": "NPM1 - ALK ALK L1122V ALK L1196M"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13328,
                "profileName": "NPM1 - ALK ALK L1122V ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3550,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13342,
                "profileName": "NPM1 - ALK ALK L1196M ALK D1203N"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3483,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13342,
                "profileName": "NPM1 - ALK ALK L1196M ALK D1203N"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13342,
                "profileName": "NPM1 - ALK ALK L1196M ALK D1203N"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3442,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Alunbrig (brigatinib) treatment in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13342,
                "profileName": "NPM1 - ALK ALK L1196M ALK D1203N"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3467,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",
            "molecularProfile": {
                "id": 13342,
                "profileName": "NPM1 - ALK ALK L1196M ALK D1203N"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 3791,
                    "pubMedId": 25421750,
                    "title": "Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25421750"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5707,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Alunbrig (brigatinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5706,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5703,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, introduction of an additional ALK mutation L1198F in transformed cells expressing ALK L1196M in the context of EML4-ALK reduced resistance to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5705,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5704,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",
            "molecularProfile": {
                "id": 21376,
                "profileName": "EML4 - ALK ALK L1196M ALK L1198F"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5143,
                    "pubMedId": 26698910,
                    "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26698910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14083,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1269A in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 28870,
                "profileName": "EML4 - ALK ALK L1196M ALK G1269A"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12721,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a patient with non-small cell lung cancer harboring EML4-ALK demonstrated a partial response when treated with Xalkori (crizotinib), however, after 6 months the patient progressed and was found to harbor two secondary resistance mutations, ALK G1269A and ALK L1196M (PMID: 23344087).",
            "molecularProfile": {
                "id": 28870,
                "profileName": "EML4 - ALK ALK L1196M ALK G1269A"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 2523,
                    "pubMedId": 23344087,
                    "title": "Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23344087"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK C1156Y in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 28872,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12724,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK treated on a clinical trial achieved a partial response when treated with Xalkori (crizotinib), however, after 5 months, the patient progressed and was found to harbor secondary resistance mutations, ALK C1156Y and ALK L1196M (PMID: 20979473; NCT00585195).",
            "molecularProfile": {
                "id": 28872,
                "profileName": "EML4 - ALK ALK C1156Y ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 912,
                    "pubMedId": 20979473,
                    "title": "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20979473"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18108,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, ALK L1196M was identified in 17% (12/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16000,
                    "pubMedId": 31358542,
                    "title": "Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31358542"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18111,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, ALK L1196M was identified in 38% (11/29) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Lorbrena (lorlatinib) treatment (PMID: 31358542).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16000,
                    "pubMedId": 31358542,
                    "title": "Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31358542"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12860,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ALK L1196M was identified in biopsies from a non-small cell lung cancer patient harboring an ALK rearrangement who developed resistance to Xalkori (crizotinib) (PMID: 22277784).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 683,
                    "pubMedId": 22277784,
                    "title": "Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22277784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12853,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, four non-small cell lung cancer patients harboring an ALK rearrangement responded to Xalkori (crizotinib) therapy, but then progressed, and were found to have acquired ALK L1196M (PMID: 25724526).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3718,
                    "pubMedId": 25724526,
                    "title": "Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25724526"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18106,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, ALK L1196M was identified in 22% (10/46) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received Alecensa (alectinib) treatment (PMID: 31358542).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16000,
                    "pubMedId": 31358542,
                    "title": "Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31358542"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18107,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, ALK L1196M was identified in 17% (12/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16000,
                    "pubMedId": 31358542,
                    "title": "Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31358542"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19777,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in disease progression after 4 months of therapy in a patient with ALK rearranged lung adenocarcinoma, ALK L1196M was detected in the biopsies at disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18109,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, ALK L1196M was identified in 17% (12/70) of plasma samples at disease progression in ALK-positive non-small cell lung cancer patients who received second-generation ALK TKI treatment, including Alecensa (alectinib) (n=46), Zykadia (ceritinib) (n=4), Alunbrig (brigatinib) (n=3), Ensartinib (X-396) (n=1), or more than 2 lines of TKIs (n=16) (PMID: 31358542).",
            "molecularProfile": {
                "id": 28942,
                "profileName": "ALK rearrange ALK L1196M"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16000,
                    "pubMedId": 31358542,
                    "title": "Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31358542"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14072,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK I1171S was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29926,
                "profileName": "EML4 - ALK ALK I1171S ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14074,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK F1174C was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29927,
                "profileName": "EML4 - ALK ALK F1174C ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14075,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK F1174L was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29928,
                "profileName": "EML4 - ALK ALK F1174L ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14076,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK F1174V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29929,
                "profileName": "EML4 - ALK ALK F1174V ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14077,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK I1179V was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29931,
                "profileName": "EML4 - ALK ALK I1179V ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14078,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK L1256F was identified as a compound mutation in transformed cells expressing ALK L1196M in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29934,
                "profileName": "EML4 - ALK ALK L1196M ALK L1256F"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14080,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALK L1196M was identified as a compound mutation in transformed cells expressing ALK G1202R in the context of EML4-ALK that acquired resistance to Lorlatinib (PF-06463922) in culture (PMID: 29650534).",
            "molecularProfile": {
                "id": 29936,
                "profileName": "EML4 - ALK ALK L1196M ALK G1202R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14087,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, an ALK-positive non-small cell lung cancer patient harboring ALK G1202R ALK L1196M developed resistance to Lorlatinib (PF-06463922) after initial response (PMID: 29650534).",
            "molecularProfile": {
                "id": 29942,
                "profileName": "ALK rearrange ALK G1202R ALK L1196M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11440,
                    "pubMedId": 29650534,
                    "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15719,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ALK G1202R and ALK L1196M were identified at disease progression while on Alunbrig (brigatinib) treatment in liquid biopsy of a patient with ALK-positive non-small cell lung cancer also harboring an ALK V1180L (PMID: 29935304).",
            "molecularProfile": {
                "id": 31174,
                "profileName": "ALK rearrange ALK V1180L ALK L1196M ALK G1202R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11688,
                    "pubMedId": 29935304,
                    "title": "Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29935304"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19682,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, Ensartinib (X-396) treatment resulted in an objective response in 25% (1/12, all partial responses) and stable disease in 67% (8/12) of patients with ALK-positive non-small cell lung cancer harboring ALK L1196M (PMID: 31628085; NCT0321569).",
            "molecularProfile": {
                "id": 34419,
                "profileName": "ALK L1196M ALK pos"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16908,
                    "pubMedId": 31628085,
                    "title": "Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31628085"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19781,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring ALK rearrangement and acquired ALK L1196M, ALK D1203N mutations demonstrated primary resistance to Lorbrena (lorlatinib) treatment, resulted in immediate disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 34513,
                "profileName": "ALK L1196M ALK D1203N ALK rearrange"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19779,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zykadia (ceritinib) treatment resulted in disease progression after 5 months of therapy in a patient with lung adenocarcinoma harboring ALK rearrangement and an acquired ALK L1196M, ALK D1203N was detected in the biopsies at disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 34513,
                "profileName": "ALK L1196M ALK D1203N ALK rearrange"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19801,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK L1196M and ALK D1203N compound mutation in the context of EML4-ALK were resistant to Lorbrena (lorlatinib) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34524,
                "profileName": "EML4 - ALK ALK L1196M ALK D1203N"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 537,
            "profileName": "ALK L1196M",
            "profileTreatmentApproaches": [
                {
                    "id": 8520,
                    "name": "ALK Inhibitor",
                    "profileName": "ALK L1196M"
                }
            ]
        },
        {
            "id": 5335,
            "profileName": "EML4 - ALK ALK L1196M",
            "profileTreatmentApproaches": [
                {
                    "id": 16809,
                    "name": "Lorlatinib",
                    "profileName": "EML4 - ALK ALK L1196M"
                },
                {
                    "id": 16811,
                    "name": "Entrectinib",
                    "profileName": "EML4 - ALK ALK L1196M"
                },
                {
                    "id": 16814,
                    "name": "Ensartinib",
                    "profileName": "EML4 - ALK ALK L1196M"
                },
                {
                    "id": 16810,
                    "name": "Ceritinib",
                    "profileName": "EML4 - ALK ALK L1196M"
                },
                {
                    "id": 16812,
                    "name": "Brigatinib",
                    "profileName": "EML4 - ALK ALK L1196M"
                },
                {
                    "id": 16813,
                    "name": "Repotrectinib",
                    "profileName": "EML4 - ALK ALK L1196M"
                }
            ]
        },
        {
            "id": 10720,
            "profileName": "ALK fusion ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13320,
            "profileName": "NPM1 - ALK ALK L1196M",
            "profileTreatmentApproaches": [
                {
                    "id": 16856,
                    "name": "Brigatinib",
                    "profileName": "NPM1 - ALK ALK L1196M"
                },
                {
                    "id": 16857,
                    "name": "Ceritinib",
                    "profileName": "NPM1 - ALK ALK L1196M"
                }
            ]
        },
        {
            "id": 13328,
            "profileName": "NPM1 - ALK ALK L1122V ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13334,
            "profileName": "ALK L1196M ALK S1206C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13342,
            "profileName": "NPM1 - ALK ALK L1196M ALK D1203N",
            "profileTreatmentApproaches": [
                {
                    "id": 16858,
                    "name": "ASP3026",
                    "profileName": "NPM1 - ALK ALK L1196M ALK D1203N"
                }
            ]
        },
        {
            "id": 21376,
            "profileName": "EML4 - ALK ALK L1196M ALK L1198F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28870,
            "profileName": "EML4 - ALK ALK L1196M ALK G1269A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28872,
            "profileName": "EML4 - ALK ALK C1156Y ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28942,
            "profileName": "ALK rearrange ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29926,
            "profileName": "EML4 - ALK ALK I1171S ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29927,
            "profileName": "EML4 - ALK ALK F1174C ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29928,
            "profileName": "EML4 - ALK ALK F1174L ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29929,
            "profileName": "EML4 - ALK ALK F1174V ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29931,
            "profileName": "EML4 - ALK ALK I1179V ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29933,
            "profileName": "EML4 - ALK ALK L1196M ALK L1198H",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29934,
            "profileName": "EML4 - ALK ALK L1196M ALK L1256F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29936,
            "profileName": "EML4 - ALK ALK L1196M ALK G1202R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29942,
            "profileName": "ALK rearrange ALK G1202R ALK L1196M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31174,
            "profileName": "ALK rearrange ALK V1180L ALK L1196M ALK G1202R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34419,
            "profileName": "ALK L1196M ALK pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34513,
            "profileName": "ALK L1196M ALK D1203N ALK rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34524,
            "profileName": "EML4 - ALK ALK L1196M ALK D1203N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102059,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29220765G>T",
            "cDna": "c.3586C>A",
            "protein": "p.L1196M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}